biologic

N/A

HPC, Cord Blood

Loss of exclusivityJanuary 2028projected — 12-year biologic exclusivity estimate

CompanyBLOODWORKS →See this company's full patent-cliff portfolio

Drug detail

Brand name	N/A
Active ingredient	HPC, Cord Blood
Strength	5X10^8 NUCLEATED CELLS CONTENT WITH 85% VIABILITY & 1.25X10^6 VIABLE CD34+ CELLS (PRE-CRYOPRESERVATION)
Dosage form	Injection
Route	Intravenous
Modality	Biologic
FDA approval	January 2016
Marketing status	Rx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.